This brief report presents self-reports of recovery among adults aged 18 and older in the United States who thought they ever had a problem with their use of drugs or alcohol and/or mental health. These findings provide a clearer characterization of the factors associated with recovery among adults and how future efforts can foster a whole-health approach to sustain recovery from mental health and substance use conditions.

This document updates SAMHSA’s 2018 document and outlines best practices for the implementation and operation of recovery housing. These best practices are intended to serve as a tool for states, governing bodies, providers, recovery house operators, and other interested stakeholders to improve the health of their citizens, reduce incidence of overdose, and promote recovery housing as a key support strategy in achieving and sustaining recovery.

This resource provides information to primary care providers and practices on how to implement opioid use disorder treatment using buprenorphine. It identifies common barriers and strategies to overcome them. It documents step-by-step tactics to support buprenorphine implementation.

A guide for community leaders to use when planning to implement the “Talk. They Hear You.” campaign in their communities. The guide offers best practices and step-by-step guidance for using the campaign.

A guide for community leaders to use when planning events on underage drinking and substance use prevention for parents and caregivers, educators, and other adult role models. The guide offers best practices and sample materials for planning successful events.

A guide for community leaders to use when working with the media to promote underage drinking and substance use prevention resources for parents and caregivers, educators, and other adult role models. The guide offers best practices and sample materials for engaging the media.

The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.

This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.